Clinical Trial Update: Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of an HLA-A*2402 restricted peptide vaccine for breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HLA-A*2402 Restricted Peptide Vaccine Therapy

Snippet

Sponsor: Tokyo University | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED